Oregon Public Employees Retirement Fund Sells 288 Shares of RadNet, Inc. (NASDAQ:RDNT)

Oregon Public Employees Retirement Fund lowered its position in RadNet, Inc. (NASDAQ:RDNT) by 1.9% in the 4th quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 15,279 shares of the medical research company’s stock after selling 288 shares during the period. Oregon Public Employees Retirement Fund’s holdings in RadNet were worth $1,067,000 as of its most recent SEC filing.

Several other institutional investors have also recently made changes to their positions in the company. Covestor Ltd grew its stake in shares of RadNet by 10,875.0% in the 3rd quarter. Covestor Ltd now owns 439 shares of the medical research company’s stock worth $30,000 after buying an additional 435 shares during the last quarter. USA Financial Formulas purchased a new stake in RadNet during the 4th quarter valued at $30,000. Fifth Third Bancorp boosted its stake in RadNet by 84.3% during the 4th quarter. Fifth Third Bancorp now owns 667 shares of the medical research company’s stock valued at $47,000 after purchasing an additional 305 shares during the last quarter. Peterson Financial Group Inc. purchased a new stake in RadNet during the 3rd quarter valued at $90,000. Finally, IFP Advisors Inc boosted its stake in RadNet by 39.1% during the 4th quarter. IFP Advisors Inc now owns 1,697 shares of the medical research company’s stock valued at $119,000 after purchasing an additional 477 shares during the last quarter. Institutional investors own 77.90% of the company’s stock.

Wall Street Analysts Forecast Growth

RDNT has been the topic of several recent analyst reports. Jefferies Financial Group cut their target price on RadNet from $100.00 to $80.00 and set a “buy” rating on the stock in a research note on Wednesday, January 15th. Barclays cut their target price on RadNet from $85.00 to $74.00 and set an “overweight” rating on the stock in a research note on Wednesday, January 22nd. Finally, Truist Financial reiterated a “buy” rating and set a $88.00 target price (down from $94.00) on shares of RadNet in a research note on Wednesday, January 22nd. One investment analyst has rated the stock with a sell rating, four have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $75.50.

RadNet Price Performance

NASDAQ RDNT opened at $55.47 on Friday. The business’s fifty day moving average price is $65.43 and its 200-day moving average price is $69.00. The stock has a market capitalization of $4.11 billion, a price-to-earnings ratio of -792.32 and a beta of 1.79. The company has a debt-to-equity ratio of 0.89, a current ratio of 2.16 and a quick ratio of 2.16. RadNet, Inc. has a 1-year low of $37.04 and a 1-year high of $93.65.

RadNet (NASDAQ:RDNT) last announced its earnings results on Thursday, February 27th. The medical research company reported $0.22 EPS for the quarter, topping analysts’ consensus estimates of $0.21 by $0.01. RadNet had a positive return on equity of 4.29% and a negative net margin of 0.25%. The company had revenue of $477.10 million for the quarter, compared to analysts’ expectations of $459.42 million. On average, equities analysts predict that RadNet, Inc. will post 0.56 earnings per share for the current year.

RadNet Profile

RadNet, Inc, together with its subsidiaries, provides outpatient diagnostic imaging services in the United States. The company operates in two segments: Imaging Centers and Artificial Intelligence. Its services include magnetic resonance imaging, computed tomography, positron emission tomography, nuclear medicine, mammography, ultrasound, diagnostic radiology, fluoroscopy, and other related procedures, as well as multi-modality imaging services.